A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata
Mude Hemalatha, Tarun Narang, Muthu Sendhil Kumaran, Vinod Kumar, Hitaishi Mehta, Nusrat Shafiq, Daljit Kaur, Sunil Dogra · 2026
Read A Pilot Randomized Controlled Trial Comparing the Efficacy and Safety of Oral Tofacitinib Versus Methotrexate In Moderate-to-Severe Alopecia Areata by Mude Hemalatha, Tarun Narang, Muthu Sendhil Kumaran, Vinod Kumar, Hitaishi Mehta, Nusrat Shafiq, Daljit Kaur, Sunil Dogra (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13395296.txt.
Description
Mude Hemalatha and co-authors run, in 2026, a pilot trial for patchy hair loss that resists standard care. Thirty-six adults with severe alopecia areata took either tofacitinib pills or weekly methotrexate for six months. Hair loss was scored with a standard scalp scale, and patients rated their own regrowth. Mood and life quality were tracked too.
Half of the tofacitinib group reached a low hair loss score, versus one third on methotrexate. Near-full regrowth also favoured tofacitinib, though gaps were not firm in this small trial. Both groups felt better in mood and daily life. Side effects were like in count for both drugs. The authors call for a larger trial to settle the contest.
Catalog record
| CREATOR | Mude Hemalatha, Tarun Narang, Muthu Sendhil Kumaran, Vinod Kumar, Hitaishi Mehta, Nusrat Shafiq, Daljit Kaur, Sunil Dogra |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20035 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |